ClinicalTrialsFinder
RecruitingNCT06653062

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

Evaluation of Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Minimal Residual Disease (MRD) Assessment and Recurrence Monitoring in Hepatocellular Carcinoma (HCC)

Sponsor

Tongji Hospital

Enrollment

50 participants

Start Date

Nov 18, 2024

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma (HCC)

Summary

This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD) assessment and recurrence monitoring in patients with hepatocellular carcinoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a new type of blood test — measuring tumor-derived mitochondrial DNA (ct-mtDNA) — can be used to monitor for the return of liver cancer (hepatocellular carcinoma, or HCC) after treatment, potentially as a less invasive alternative to imaging. **You may be eligible if...** - You have a confirmed diagnosis of liver cancer (hepatocellular carcinoma) - Your diagnosis meets recognized international guidelines for HCC - You have at least one measurable tumor on imaging - You are expected to live at least 12 months **You may NOT be eligible if...** - You have a different type of liver cancer - You do not have measurable disease on imaging - Your expected survival is less than 12 months - You are unable or unwilling to provide blood samples for monitoring Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPlasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis

Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients. Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence.

Locations(1)

Tongji Hospital

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06653062

Related Trials

A Phase 1 Study of the Safety and Tolerability of CTX-10726

NCT074198413 locations

Computer Guided Microwave Liver Ablation

NCT072268692 locations

DEB-TACE vs cTACE in HCC After TIPS

NCT073228481 location

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

NCT070751202 locations

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

NCT074227531 location